Connection

Jean-Charles Soria to ErbB Receptors

Back to Details
This is a "connection" page, showing publications Jean-Charles Soria has written about ErbB Receptors.
Jean-Charles Soria
Connection Strength
1.543
ErbB Receptors
  1. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018 01 11; 378(2):113-125.
    View in: PubMed
    Score: 0.591
  2. Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses. J Clin Oncol. 2017 Dec 20; 35(36):4027-4034.
    View in: PubMed
    Score: 0.586
  3. Osimertinib in EGFR Mutation-Positive Advanced NSCLC. N Engl J Med. 2018 03 29; 378(13):1262-1263.
    View in: PubMed
    Score: 0.152
  4. Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy. J Clin Oncol. 2017 Jun 20; 35(18):2018-2027.
    View in: PubMed
    Score: 0.142
  5. A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours. Eur J Cancer. 2018 11; 104:1-8.
    View in: PubMed
    Score: 0.039
  6. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. 2016 Apr 02; 387(10026):1415-1426.
    View in: PubMed
    Score: 0.033
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.